NEW YORK (GenomeWeb News) — Ferrer in Code will distribute Agendia’s MammaPrint breast cancer recurrence assay and its CupPrint cancer of unknown primary test in Spain, Agendia said today.
Agendia CEO Bernhard Sixt said the partners are currently discussing “future steps in order to intensify the co-operation in other parts of the world.”
Ferrer in Code is a subsidiary of the pharmaceutical company Ferrer.
Financial terms of the agreement were not released.